A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

  • 5/13/2019 – Regeneron Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 5/13/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at Cantor Fitzgerald from $441.00 to $405.00. They now have a “neutral” rating on the stock.
  • 5/8/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $412.00 to $375.00. They now have a “market perform” rating on the stock.
  • 5/8/2019 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00.
  • 5/8/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $420.00 to $389.00. They now have an “equal weight” rating on the stock.
  • 5/8/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at UBS Group AG from $480.00 to $440.00. They now have a “buy” rating on the stock.
  • 5/7/2019 – Regeneron Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $435.00 price target on the stock.
  • 5/7/2019 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $353.00 price target on the stock.
  • 4/25/2019 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/17/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at Jefferies Financial Group Inc from $376.00 to $343.00. They now have a “hold” rating on the stock.
  • 4/16/2019 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

REGN traded down $3.10 during trading on Friday, reaching $304.94. The stock had a trading volume of 755,536 shares, compared to its average volume of 785,298. The company has a current ratio of 4.58, a quick ratio of 3.78 and a debt-to-equity ratio of 0.08. The company has a market cap of $33.42 billion, a price-to-earnings ratio of 15.40, a price-to-earnings-growth ratio of 1.44 and a beta of 1.08. Regeneron Pharmaceuticals Inc has a one year low of $291.10 and a one year high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). The firm had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. Regeneron Pharmaceuticals’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company posted $4.67 EPS. On average, analysts predict that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current year.

In other news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total transaction of $305,930.00. Following the completion of the transaction, the director now directly owns 11,323 shares in the company, valued at $3,464,045.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The disclosure for this sale can be found here. In the last quarter, insiders sold 141,968 shares of company stock valued at $57,360,056. 11.84% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Joel Isaacson & Co. LLC increased its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the first quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $1,249,000 after acquiring an additional 25 shares in the last quarter. Diversified Trust Co boosted its position in shares of Regeneron Pharmaceuticals by 0.8% during the fourth quarter. Diversified Trust Co now owns 3,630 shares of the biopharmaceutical company’s stock valued at $1,356,000 after buying an additional 30 shares during the last quarter. Cornerstone Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3.7% during the first quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 30 shares during the last quarter. Comprehensive Portfolio Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 4.1% during the first quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 33 shares during the last quarter. Finally, Kaizen Advisory LLC boosted its position in shares of Regeneron Pharmaceuticals by 21.2% during the fourth quarter. Kaizen Advisory LLC now owns 200 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 35 shares during the last quarter. Hedge funds and other institutional investors own 67.63% of the company’s stock.

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Depreciation

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.